#MNMD

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering Mind Medicine Inc., a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 18,375,000 common shares, without par value, at a public offering price of $12.25 per common share. The gross proceeds to MindMed from the offering, before...

4 months ago

#MNMD Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

www.stocktitan.net/news/MNMD/mind-medicine-...

0 0 0 0

7 months ago

#MNMD #^GSPC #37d8a6de-2185-44c7-8a8d-d1cd49dcec67 #investing

Origin | Interest | Match

0 0 0 0

7 months ago

#MNMD #3f268d68-df2e-41c8-a162-da57f6836332 #earningscall-transcripts

Origin | Interest | Match

0 0 0 0

MindMed Reports Strong Q2 2025 Results | The Motley Fool

7 months ago

#MNMD #8bfe588f-a24b-4380-ae02-9f104e4aa15d #data-news

Origin | Interest | Match

0 0 0 0

7 months ago

#MNMD #2022eba6-b59e-4d89-b628-4791406c4ffb #investing

Origin | Interest | Match

0 0 0 0

Is Mind Medicine stock a buy? Roth Capital Markets analyst Jason Wittes maintained a “Buy” rating and $36 price target, highlighting the company’s funding runway

7 months ago

Is Mind Medicine stock a buy? Mind Medicine (Mind Medicine (MindMed) Stock Quote, Chart, News, Analysts, Financials NASDAQ:MNMD) reported second-quarter 2025 results on August 4, with a focus on co...

#All #posts #Analysts #Life #Sciences #mnmd

Origin | Interest | Match

0 0 0 0

WealthWise

@wealthwise-dca.bsky.social

7 months ago

Psychedelic drug stocks surged after Bloomberg News reported AbbVie is in talks to acquire Gilgamesh Pharmaceuticals in a ~$1B deal.

#ATAI #CMPS #MNMD #ATAIStock #CMPSStock #MNMDStock #Psychedelic #PsychedelicDrugs #PsychedelicStocks #PsychedelicMedicines
$ATAI $CMPS $MNMD $ABBV

0 0 0 0

MindMed Reports Q2 2025 Financial Results and Business Updates MindMed (NASDAQ: MNMD) reported Q2 2025 financial results and business updates, highlighting strong progress in its clinical trials. The company is advancing three pivotal Phase 3 trials of MM120 ODT for Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD), with data expected in 2026. Cash position stands at $237.9 million, sufficient to fund operations into 2027.Key financial metrics include R&D expenses of $29.8 million (up from $14.6M YoY) and a net loss of $42.7 million (compared to $5.9M in Q2 2024). The company strengthened its leadership team by appointing Brandi L. Roberts as CFO and continues to show strong enrollment across all clinical trials, with Phase 3 Voyage trial data anticipated in 1H 2026, followed by Panorama and Emerge trials in 2H 2026.

7 months ago

#MNMD MindMed Reports Q2 2025 Financial Results and Business Updates

www.stocktitan.net/news/MNMD/mind-med-repor...

0 0 0 0

WealthWise

@wealthwise-dca.bsky.social

8 months ago

Compass Pathways shares fell ~46% on Monday after releasing Phase 3 data for its psilocybin-based treatment (COMP360) targeting treatment-resistant depression, which met its primary endpoint but disappointed investors expecting stronger efficacy.

#CMPS #CMPSStock #CMPSNews #ATAI #MNMD #ATAIStock

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Tue May 20th - #XNEX #TELA #SBC #QIPT #PANL #MNMD #LAES #KOSS #HOWL #VANI #GAN #FENC #ETNB #CMPS #ARQQ #XYF #VCSA #PGRE #NGL - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

9 months ago

www.fool.com/investing/2025/05/20/why...

#MNMD #1b42011a-4b34-4608-901f-924bd7306c3b #investing

Result Details

0 0 0 0

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates MindMed (NASDAQ: MNMD) reported its Q1 2025 financial results and business updates, highlighting significant progress in its Phase 3 clinical trials. The company has initiated three pivotal Phase 3 trials for MM120 ODT: Voyage and Panorama for Generalized Anxiety Disorder (GAD), and Emerge for Major Depressive Disorder (MDD). Topline data is expected in 1H 2026 for Voyage and 2H 2026 for Panorama and Emerge. The company appointed Matt Wiley as Chief Commercial Officer and amended its loan agreement with K2 HealthVentures, providing up to $120 million in funding. Financially, MindMed reported cash and investments of $245.5 million as of March 31, 2025, with R&D expenses increasing to $23.4 million compared to $11.7 million in Q1 2024. The company expects its current cash position to fund operations into 2027.

10 months ago

#MNMD MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

www.stocktitan.net/news/MNMD/mind-med-repor...

0 0 0 0

Breakthrough: First-Ever Phase 3 LSD Depression Trial Begins at MindMed MindMed advances revolutionary depression treatment as first patient receives MM120 in landmark Phase 3 trial. Built on promising Phase 2b results. Full analysis inside.

11 months ago

#MNMD MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

www.stocktitan.net/news/MNMD/mind-med-annou...

0 0 0 0

1 year ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #GME 74% OTM
2. #CAPR 65% OTM
3. #MNMD 63% OTM
4. #MSTR 62% OTM
5. #BKSY 54% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

Can MindMed's $273M War Chest Transform Anxiety Treatment? Phase 3 Trials Signal Major Momentum Strong balance sheet supports two Phase 3 GAD trials and upcoming MDD study. R&D investment increases as breakthrough therapy program advances toward commercialization.

1 year ago

#MNMD MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

www.stocktitan.net/news/MNMD/mind-med-repor...

0 0 0 0

1 year ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#MNMD, #IREN, #COIN, #ASTS, #IONQ

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 year ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #MSTR 86% OTM
2. #GME 85% OTM
3. #MNMD 63% OTM
4. #RGTI 40% OTM
5. #C 38% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 year ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #MSTR 102% OTM
2. #WULF 60% OTM
3. #CPIX 49% OTM
4. #MNMD 48% OTM
5. #CGC 42% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 year ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CPIX, #DJT, #MNMD, #OKLO, #QBTS

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 year ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #CPIX 49% OTM
2. #MNMD 48% OTM
3. #DJT 48% OTM
4. #SMCI 34% OTM
5. #OKLO 33% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0